Subgroup analysis of the phase II randomized MCL-002 (SPRINT) study of lenalidomide vs investigator's choice in relapsed/refractory mantle cell lymphoma

被引：0
|
作者：
Trneny, Marek
Lamy, Thierry
Walewski, Jan Andrzej
Belada, David
Mayer, Jiri
Radford, John A.
Jurczak, Wojciech
Morschhauser, Franck
Alexeeva, Julia
Rule, Simon
Biyukov, Tsvetan Nikolov
Patturajan, Meera
Bravo, Marie-Laure Casadebaig
Cabecadas, Jose
Arcaini, Luca
机构：
[1] Charles Univ Hosp, Dept Hematol, Prague, Czech Republic
[2] Hop Pontchaillou, Dept Hematol, Rennes, France
[3] Maria Sklodowska Curie Mem Inst & Oncol Ctr, Dept Lymphoid Malignancies, Warsaw, Poland
[4] Charles Univ Hosp & Fac Med, Dept Internal Med Hematol 4, Hradec Kralove, Czech Republic
[5] Univ Hosp Brno, Dept Internal Med Hematol & Oncol, Brno, Czech Republic
[6] Univ Manchester, Manchester, Lancs, England
[7] Christie NHS Fdn Trust, Manchester, Lancs, England
[8] Jagiellonian Univ, Dept Hematol, Krakow, Poland
[9] Ctr Hosp Univ Reg Lille, Lille, France
[10] Fed Med Res Ctr, St Petersburg, Russia
[11] Derriford Hosp, Dept Hematol, Plymouth PL6 8DH, Devon, England
[12] Celgene Sarl, Boudry, Switzerland
[13] Celgene Corp, Summit, NJ USA
[14] Inst Portugues Oncol Francisco Gentil, Serv Anat Patol, Lisbon, Portugal
[15] Fdn IRCCS Policlin San Matteo, Dept Hematol Oncol, Pavia, Italy
[16] Univ Pavia, Dept Mol Med, I-27100 Pavia, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8547
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Supportive Efficacy Analyses for the Phase 3 Study of Temsirolimus Versus Investigator's Choice Therapy for the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma
    Romaguera, Jorge
    Coiffier, Bertrand
    Crump, Michael
    Herbrecht, Raoul
    Verhoef, Gregor
    Hanushevsky, Orysia
    Strahs, Andrew
    Hewes, Becker
    Berkenblit, Anna
    Hess, Georg
    BLOOD, 2008, 112 (11) : 553 - 553
  • [22] EFFICACY AND SAFETY OF CONVENTIONAL-DOSE LENALIDOMIDE FOLLOWED BY LOW-DOSE MAINTENANCE LENALIDOMIDE FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA (MCL): RESULTS FROM A UK PHASE II STUDY
    Eve, H. E.
    Bullard, S. H.
    Rule, S. A.
    ANNALS OF ONCOLOGY, 2011, 22 : 222 - 222
  • [23] A phase II study of 90Yttrium-ibritumomab (Zevalin) for the treatment of patients with relapsed and refractory mantle cell lymphoma (MCL).
    Younes, A
    Pro, B
    Delpassand, E
    McLaughlin, P
    Romaguera, J
    Wang, M
    BLOOD, 2003, 102 (11) : 406A - 406A
  • [24] Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma
    Witzig, Thomas E.
    Zinzani, Pier Luigi
    Habermann, Thomas M.
    Tuscano, Joseph M.
    Drach, Johannes
    Ramchandren, Radhakrishnan
    Besisik, Sevgi Kalayoglu
    Takeshita, Kenichi
    Bravo, Marie-Laure Casadebaig
    Zhang, Lei
    Fu, Tommy
    Goy, Andre
    AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (10) : E575 - E583
  • [25] SINGLE-AGENT LENALIDOMIDE IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: A COMBINED ANALYSIS FROM THE MCL-001, NHL-002, AND NHL-003 STUDIES
    Witzig, T.
    Vose, J.
    Zinzani, P.
    Habermann, T.
    Tuscano, J.
    Sinha, R.
    Williams, M.
    Drach, J.
    Ramchandren, R.
    Besisik, S.
    Zhang, L.
    Cicero, S.
    Fu, T.
    Goy, A.
    HAEMATOLOGICA, 2013, 98 : 130 - 131
  • [26] Phase II study of bortezomib, cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma
    Shin, Junghoon
    Lee, Ji Yun
    Lee, Gyeong-Won
    Kim, Won Seog
    Park, Yong
    Do, Young Rok
    Kim, Dae Sik
    Kim, Ki Hwan
    Choi, Yoon Seok
    Byun, Ja Min
    Hong, Junshik
    Kim, Inho
    Yoon, Sung-Soo
    Koh, Youngil
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 202 (06) : E54 - E57
  • [27] Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma
    Maruyama, Dai
    Nagai, Hirokazu
    Fukuhara, Noriko
    Kitano, Toshiyuki
    Ishikawa, Takayuki
    Nishikawa, Tomoaki
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2019, 59 (02) : 98 - 100
  • [28] Phase II study of enzastaurin in the treatment of relapsed/refractory mantle cell lymphoma.
    Morschhausser, Frank
    Wolf, Martin
    Seymour, John
    Tilly, Herve
    Pfreundschuh, Michael
    Kluin-Nelemans, Hanneke
    Raemaekers, John
    van't Veer, Mars B.
    Milpied, Noel
    Cartron, Guillaume
    Pezzutto, Antonio
    Spencer, Andrew
    Darstein, Christelle
    Thornton, Donald
    Dreyling, Martin
    Reyes, Felix
    BLOOD, 2006, 108 (11) : 694A - 694A
  • [29] Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
    Fisher, Richard I.
    Bernstein, Steven H.
    Kahl, Brad S.
    Djulbegovic, Benjamin
    Robertson, Michael J.
    de Vos, Sven
    Epner, Elliot
    Krishnan, Amrita
    Leonard, John P.
    Lonial, Sagar
    Stadtmauer, Edward A.
    O'Connor, Owen A.
    Shi, Hongliang
    Boral, Anthony L.
    Goy, Andre
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (30) : 4867 - 4874
  • [30] Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma - the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase Ib-II Trial
    Jerkeman, Mats
    Kolstad, Arne
    Hutchings, Martin
    Pasanen, Annika
    Meriranta, Leo
    Niemann, Carsten Utoft
    Jorgensen, Rasmus Rask Kragh
    El-Galaly, Tarec Christoffer Christoffer
    Riise, Jon
    Leppa, Sirpa
    Christensen, Jacob Haaber
    Wader, Karin Fahl
    Glimelius, Ingrid
    BLOOD, 2022, 140
12345